BioPharma Dive: Brain disease startup Neumora draws more funding for ambitious research plan
Read More
Archive for Neumora in the News
Boston Business Journal: Amgen-partnered neuroscience startup rakes in another $112M
Read More
Endpoints: The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies
Read More
The Economist: Better brain biology will deliver better medicines
Read More
STAT: Backed with $500 million, a startup aims to rethink psychiatric drug development
Read More
Endpoints: ARCH unveils its Really Big Neuroscience Company with $500M, an Amgen deal and eyes on depression, Alzheimer’s and a lot more
Read More
Business Insider: A new startup created by one of biotech’s biggest VCs shows you need to go big to treat brain disorders
Read More
Biopharma Dive: Armed with half a billion dollars, a startup aims to change how brain drugs are made
Read More
Timmerman Report: Neumora Secures $500M, Amgen Deal, in Quest for Neuroscience R&D
Read More
BioCentury: Arch-backed Neumora: using data tools for precision neuroscience
Read More